Skip to search formSkip to main contentSkip to account menu

GEM231

Known as: GEM 231, GEM-231, Gene Expression Modulator 231 
A mixed backbone oligonucleotide exhibiting antitumor activity. GEM-231 is complementary to the RI alpha subunit of Protein Kinase A (PKA), resulting… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Progression to castration resistance is a major problem in the treatment of advanced prostate cancer and is likely to be driven… 
2003
2003
Abstract: GEM®231 is a second‐generation antisense oligonucleotide targeted against the RIα regulatory subunit of cAMP‐dependent… 
2003
2003
  • S. Goel, K. Desai, S. Mani
  • Clinical cancer research : an official journal of…
  • 2003
  • Corpus ID: 23338201
PURPOSE The purpose of this study was to define the safety and pharmacodynamics of GEM231, a mixed backbone antisense… 
2003
2003
PURPOSE The increased expression of RIalpha, the regulatory subunit of cyclic AMP (cAMP)-dependent protein kinase type I (PKA-I… 
2002
2002
GEM 231, a second-generation antisense oligonucleotide targeted against the RIalpha subunit of protein kinase A (PKA) was co… 
2002
2002
The RIalpha-subunit of cAMP-dependent protein kinase (PKA) is overexpressed in various human cancers and PKA has been suggested… 
Highly Cited
2000
Highly Cited
2000
GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an… 
2000
2000
Biodistribution and metabolism of a mixed backbone oligonucleotide (MBO), GEM 231, targeted to the RIalpha subunit of protein… 
Review
2000
Review
2000
  • J. Blay
  • Current opinion in molecular therapeutics
  • 2000
  • Corpus ID: 21473171
Hybridon is conducting studies of the DNA methyltransferase gene and has identified specific sequences on mRNA as targets for…